Global Market Study on Autologous Conditioned Plasma Therapy: High Preference for Minimally-invasive Surgical Treatments Spurring Demand


Autologous Conditioned Plasma  Market
  • Published On : Nov-2020 |
  • Pages : 314 Pages |
  • Format : Autologous Conditioned Plasma  Market Autologous Conditioned Plasma  Market Autologous Conditioned Plasma  Market Autologous Conditioned Plasma  Market

Autologous conditioned plasma therapy is used to treat a range of problems, such as musculoskeletal injuries and sports injuries & trauma. Nowadays, it is widely used in treating skin ulcers, sports injuries, and for cosmetic surgeries, besides others. Growing demand for user-friendly therapy procedures is driving the expansion of the autologous conditioned plasma therapy market size.

The procedure provides excellent and effective treatment without the need for undergoing painful surgery. Autologous conditioned plasma therapy is done on an outpatient basis for saving time wasted on hospital stays, and is particularly useful for patients who require both, relief and quick healing. As such, it helps improve patient compliance to the treatment, which is an important factor driving the growth of the global autologous conditioned plasma therapy market, at a high value CAGR of around 12% through 2030.

Autologous Conditioned Plasma Therapy Market Trends

Technological Advancements Aiding Market Expansion: Technological advancements are driving the growth of the autologous conditioned plasma therapy market. For example, on June 11, 2019, EmCyte Corporation announced FDA 510(k) approval for PureBMC® Supraphysiologic Concentrating System for preparing a cell concentrate from bone marrow aspirate and platelet concentrate. This clinical technology optimizes the double spin technique, capturing the essential requirements needed to exceed the clinical requisite for deliverable platelets.

In addition, rising popularity of autologous conditioned plasma fibrin therapy is another factor driving the growth of the autologous conditioned plasma therapy market. It has extensive growth factors and rich platelet content in the form of fibrin membranes, which are free from anti-coagulants or other artificial bio-chemical modifications. P-PRF therapy is known as a second generation platelet concentrate, which promotes rapid and accelerated wound healing.

Progressive Demographic Aging of Older Population to Fuel Market Growth: Aging contributes to soft tissue degeneration and related disorders, particularly of the knee. Autologous conditioned plasma therapy is an effective treatment in knee osteoarthritis management. The elderly account for over one-third of total global hip and shoulder injuries. In the U.S., the most common joint disorder is osteoarthritis. Prevalence of symptomatic knee OA among adults 60 years of age or older is around 13% in women and 10% in men. This factor is likely to drive the global autologous conditioned plasma therapy market over the forecast period of 2020 to 2030.

Rising Incidence of Musculoskeletal Injuries to Propel Demand: The World Health Organization (WHO) states that, musculoskeletal injuries affect millions of people around the world, and is the most common cause of severe long-term pain and physical disability. However, autologous conditioned plasma therapy is an attractive and promising alternative to surgery, for treating musculoskeletal injuries by promoting safe and effective wound healing. As a result of its promising therapeutic potential and excellent regenerative properties, this therapy finds widespread clinical use for musculoskeletal injuries and related diseases.  According to a Global Burden of Disease (GBD) study, musculoskeletal disorders and injuries were the highest contributor to global disability, and accounted for 16% of all years lived with disability, and lower back pain remained the single leading cause of disability.

Prevalence of musculoskeletal conditions varies by age and diagnosis; between 20%–33% of people across the globe live with a painful musculoskeletal condition. Rising cases of musculoskeletal injuries is leading to increased demand for autologous conditioned plasma therapy for treating musculoskeletal injuries.

autologous conditioned plasma therapy market Gain More Insights about this Report

COVID-19 Impact on Autologous Conditioned Plasma Therapy Market

As the spread of COVID-19 continues, it is negatively affecting almost all industries, and has also adversely affected the autologous conditioned plasma therapy market. There has been disruptions in the supply-chain due to global restrictions. Local governments and companies are allocating funds for the expansion of existing facilities and construction of new facilities to tackle the COVID-19 pandemic.

As coronavirus has become the main focus, many pharmaceutical and biotech companies are engaged in developing a potent vaccine. This is expected to hamper the clinical development activities of leading autologous conditioned plasma therapy market players during the duration of the COVID-19 pandemic.

Analysts’ Viewpoint

An extensive analysis of the autologous conditioned plasma therapy market has brought our analysts to a conclusion that, the market is growing at a significant pace. Currently, pure platelet-rich fibrin (P-PRF) is a targeted segment for major players in the autologous conditioned plasma therapy market, due to extensive growth factors and rich platelet content in the form of fibrin membranes. North America and Europe collectively hold more than 70% of autologous conditioned plasma therapy market share as far as revenue is concerned, due to high demand and technological advancements in these regions. Emerging countries such as China and Brazil are expected to offer lucrative opportunities for the growth of the autologous conditioned plasma therapy market, owing to increasing pool of patients and rising awareness among the population.

Autologous Conditioned Plasma Therapy Market - Scope of the Report

A latest publication by Persistence Market Research (PMR) on the global autologous conditioned plasma therapy market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global autologous conditioned plasma therapy market. The study offers detailed insights on key market dynamics, which includes the drivers, restraints, trends, and opportunities in the autologous conditioned plasma therapy market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for the successful growth of the autologous conditioned plasma therapy market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR. This research study can support readers to know the demand for autologous conditioned plasma therapy and quantitative development opportunities during the study period.

The research is beneficial for shareholders in the autologous conditioned plasma therapy market, including investors and service providers, and can help them in developing suitable business strategies to flourish in the autologous conditioned plasma therapy market. The insights and wisdom presented in this PMR study can be leveraged by shareholders in the autologous conditioned plasma therapy market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the autologous conditioned plasma therapy market are also included in the current study. Depending on potential developments in the autologous conditioned plasma therapy market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this market report, minor companies and new entrants in the autologous conditioned plasma therapy industry can be aided in making suitable company choices to achieve traction in the market landscape.

Key Segments of Autologous Conditioned Plasma Therapy Market

PMR’s study on the autologous conditioned plasma therapy market offers information divided into five important segments—composition, source, indication, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Composition

  • Pure Platelet-Rich Plasma (P-PRP)
  • Leukocyte- and Platelet-Rich Plasma (LPRP)
  • Pure Platelet-Rich Fibrin (P-PRF)
  • Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Source

  • Autologous Platelet-Rich Plasma
  • Allogeneic Platelet-Rich Plasma
  • Homologues Platelet-Rich Plasma

Indication

  • Skin Ulcers
  • Bone Fractures and Grafts
  • Prostheses Surgeries
  • Oral Implantology
  • Sport Injuries & Trauma
  • Cosmetic Surgeries
  • Others

End User

  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers
  • Orthopedic & Trauma Centers
  • Research Institutes

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Autologous Conditioned Plasma Therapy Market Report

  • Which regions will continue to remain most profitable regional market for autologous conditioned plasma therapy market players?
  • Which factors will induce a change in the demand for autologous conditioned plasma therapy during the assessment period?
  • How will COVID-19 change the trends of the autologous conditioned plasma therapy market?
  • How can market players capture the low-hanging opportunities in the autologous conditioned plasma therapy market in developed regions?
  • What are the winning strategies of stakeholders in the autologous conditioned plasma therapy market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and tackle while investing in the autologous conditioned plasma therapy market?
  • What are the developmental trends in autologous conditioned plasma therapy sectors that will impact the market?
  • How can businesses in the autologous conditioned plasma therapy market avail the growth opportunities in developed and emerging economies?

Autologous Conditioned Plasma Therapy Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the autologous conditioned plasma therapy market, and reach conclusions on future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the autologous conditioned plasma therapy market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts interviewed specialized industry experts, medical professionals with autologous conditioned plasma therapy surgeries, and key executives of product manufacturing companies, who have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the autologous conditioned plasma therapy market, and makes PMR’s projections on the growth prospects of the autologous conditioned plasma therapy market more accurate and reliable.

Companies covered in Autologous Conditioned Plasma Market Report

  • Zimmer Biomet Inc.
  • Terumo Corporation
  • DePuy Synthes, Inc. (DePuy Mitek Sports Medicine)
  • AdiStem Ltd.
  • Arthrex, Inc.
  • Stryker Corporation
  • Cesca Therapeutics, Inc.
  • Biotechnology Institute BTI
  • Dr. PRP America LLC
  • EmCyte Corporation
  • Vivostat A/S
  • Regen Lab SA
  • Royal Biologics
  • Exactech, Inc.
  • Plateltex S.R.O.

Autologous Conditioned Plasma Market

Back To Top